Last reviewed · How we verify
Post-CPB Drug: Dobutamine Hydrochloride
Dobutamine is a beta-1 adrenergic agonist that increases cardiac contractility and heart rate to improve cardiac output in patients with low cardiac function.
Dobutamine is a beta-1 adrenergic agonist that increases cardiac contractility and heart rate to improve cardiac output in patients with low cardiac function. Used for Inotropic support in the immediate post-cardiopulmonary bypass period, Acute decompensated heart failure with reduced cardiac output.
At a glance
| Generic name | Post-CPB Drug: Dobutamine Hydrochloride |
|---|---|
| Also known as | Transthoracic or 2D Echocardiogram, Transesophageal Echocardiogram (TEE) |
| Sponsor | University Health Network, Toronto |
| Drug class | Beta-1 adrenergic agonist |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dobutamine selectively stimulates beta-1 adrenergic receptors on cardiac myocytes, increasing intracellular cAMP and enhancing myocardial contractility. It is commonly used in the post-cardiopulmonary bypass period to support cardiac function and improve hemodynamics when the heart has been temporarily stopped and requires inotropic support to resume adequate perfusion.
Approved indications
- Inotropic support in the immediate post-cardiopulmonary bypass period
- Acute decompensated heart failure with reduced cardiac output
Common side effects
- Tachycardia
- Arrhythmias
- Hypertension
- Headache
- Tremor
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: